薬物動態
Print ISSN : 0916-1139
新規5-HT3受容体拮抗薬Y-25130の体内動態(第1報): 14C-Y-25130静脈内投与時のラットにおける血漿中濃度,分布,代謝および排泄
西峯 秀夫三浦 誠二衛藤 公洋岡部 次夫有馬 徳行
著者情報
ジャーナル フリー

1992 年 7 巻 6 号 p. 661-673

詳細
抄録

The plasma concentration, distribution, metabolism and excretion of 14C-Y-25130 were investigated in rats after intravenous administration.
1. Plasma levels of radioactivity (14C) decreased multiexponentially at the dose levels of 0.4, 1, 2, 10mg/kg, and the terminal half-lives (t1/2z) were 8.4 -9.5 hours. No dose or sex differences in t1/2z were observed. The areas under the plasma level-time curve were approximately proportional to the dose. Tissue levels of 14C were high in the liver, lung, kidney, pituitary gland, submaxillary gland, pancreas, stomach, adrenal, bone marrow, thyroid and spleen. Radioactivity rapidly disappeared from all tissues and was not detected in carcasses 96 hours after administration, suggesting no accumulation of 14C.
2. Binding rates of 14C to plasma proteins were 42.8-44.6% during 0.25-2 hours after administration.
3. Four days after administration to male rats at a dose of 1 mg/kg, urinary and fecal excretion of 14C were 45.5% and 52.9% of administered dose, respectively. At this dose, urinary excretion was much higher in female rats than in male rats. The excretion in male rats increased significantly at the highest dose level. Unchanged drug was found mainly in urine, while the unchanged drug, M1 and M3 were present in feces. The amount of unchanged drug in urine was much higher in female rats than in male rats. This amount increased at the highest dose level in male rats.
4. Fourty eight hours after administration to bile-duct cannulated male rats, 42.0% of the dose was excreted in bile and 12.8% in feces. This result indicates that another direct excretion route to the gastrointestinal tract exist besides the bile. About 13% of 14C excreted in bile was reabsorbed from the intestines by the enterohepatic circulation.

著者関連情報
© 日本薬物動態学会
次の記事
feedback
Top